studies

melanoma (ML), Ipilimumab (10 mg/kg) vs. anti-PD-(L)1, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 238, 2017 (REV) 1.15 [0.87; 1.51] 1.15[0.87; 1.51]CheckMate 238, 2017 (REV)10%906NAnot evaluable MFSdetailed resultsCheckMate 238, 2017 (REV) 1.37 [1.04; 1.80] 1.37[1.04; 1.80]CheckMate 238, 2017 (REV)10%735NAnot evaluable RFS (extension)detailed resultsCheckMate 238, 2017 (REV) 1.41 [1.18; 1.69] 1.41[1.18; 1.69]CheckMate 238, 2017 (REV)10%906NAnot evaluable RFS/DFSdetailed resultsCheckMate 238, 2017 (REV) 1.54 [1.21; 1.96] 1.54[1.21; 1.96]CheckMate 238, 2017 (REV)10%906NAnot evaluable AE (any grade)detailed resultsCheckMate 238, 2017 (REV) 2.04 [0.81; 5.09] 2.04[0.81; 5.09]CheckMate 238, 2017 (REV)10%905NAnot evaluable AE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 3.61 [2.72; 4.78] 3.61[2.72; 4.78]CheckMate 238, 2017 (REV)10%905NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsCheckMate 238, 2017 (REV) 6.88 [4.79; 9.89] 6.88[4.79; 9.89]CheckMate 238, 2017 (REV)10%905NAnot evaluable AE leading to treatment discontinuation (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 9.18 [5.67; 14.85] 9.18[5.67; 14.85]CheckMate 238, 2017 (REV)10%905NAnot evaluable TRAE (any grade)detailed resultsCheckMate 238, 2017 (REV) 3.98 [2.35; 6.74] 3.98[2.35; 6.74]CheckMate 238, 2017 (REV)10%905NAnot evaluable TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 5.05 [3.67; 6.97] 5.05[3.67; 6.97]CheckMate 238, 2017 (REV)10%905NAnot evaluable TRAE leading to death (grade 5)detailed resultsCheckMate 238, 2017 (REV) 4.00 [0.18; 89.05] 4.00[0.18; 89.05]CheckMate 238, 2017 (REV)10%905NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 238, 2017 (REV) 8.53 [5.76; 12.63] 8.53[5.76; 12.63]CheckMate 238, 2017 (REV)10%905NAnot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 11.69 [6.83; 20.02] 11.69[6.83; 20.02]CheckMate 238, 2017 (REV)10%905NAnot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 2.00 [0.07; 59.70] 2.00[0.07; 59.70]CheckMate 238, 2017 (REV)10%905NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 2.00 [0.37; 11.00] 2.00[0.37; 11.00]CheckMate 238, 2017 (REV)10%905NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 2.00 [0.18; 22.14] 2.00[0.18; 22.14]CheckMate 238, 2017 (REV)10%905NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 4.02 [0.45; 36.09] 4.02[0.45; 36.09]CheckMate 238, 2017 (REV)10%905NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 0.50 [0.02; 14.89] 0.50[0.02; 14.89]CheckMate 238, 2017 (REV)10%905NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 6.67 [2.97; 14.99] 6.67[2.97; 14.99]CheckMate 238, 2017 (REV)10%905NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 2.00 [0.37; 11.00] 2.00[0.37; 11.00]CheckMate 238, 2017 (REV)10%905NAnot evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed resultsCheckMate 238, 2017 (REV) 9.92 [4.91; 20.07] 9.92[4.91; 20.07]CheckMate 238, 2017 (REV)10%905NAnot evaluable Headache TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 7.08 [0.87; 57.77] 7.08[0.87; 57.77]CheckMate 238, 2017 (REV)10%905NAnot evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed resultsCheckMate 238, 2017 (REV) 6.73 [3.15; 14.39] 6.73[3.15; 14.39]CheckMate 238, 2017 (REV)10%905NAnot evaluable Hypersensitivity TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 0.50 [0.02; 14.89] 0.50[0.02; 14.89]CheckMate 238, 2017 (REV)10%905NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 1.00 [0.06; 16.00] 1.00[0.06; 16.00]CheckMate 238, 2017 (REV)10%905NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 5.60 [1.23; 25.41] 5.60[1.23; 25.41]CheckMate 238, 2017 (REV)10%905NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 2.00 [0.18; 22.14] 2.00[0.18; 22.14]CheckMate 238, 2017 (REV)10%905NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 9.85 [2.28; 42.54] 9.85[2.28; 42.54]CheckMate 238, 2017 (REV)10%905NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 5.44 [2.07; 14.31] 5.44[2.07; 14.31]CheckMate 238, 2017 (REV)10%905NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 18.30 [1.06; 316.70] 18.30[1.06; 316.70]CheckMate 238, 2017 (REV)10%905NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 0.50 [0.02; 14.89] 0.50[0.02; 14.89]CheckMate 238, 2017 (REV)10%905NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 10.08 [0.55; 185.02] 10.08[0.55; 185.02]CheckMate 238, 2017 (REV)10%905NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 4.00 [0.18; 89.05] 4.00[0.18; 89.05]CheckMate 238, 2017 (REV)10%905NAnot evaluable Rash TRAE (grade 3-4)detailed resultsCheckMate 238, 2017 (REV) 2.85 [1.02; 7.98] 2.85[1.02; 7.98]CheckMate 238, 2017 (REV)10%905NAnot evaluable Renal and urinary disorders TRAE (grade 3-4) detailed resultsCheckMate 238, 2017 (REV) 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 238, 2017 (REV)10%905NAnot evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed resultsCheckMate 238, 2017 (REV) 8.04 [0.42; 152.61] 8.04[0.42; 152.61]CheckMate 238, 2017 (REV)10%905NAnot evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed resultsCheckMate 238, 2017 (REV) 5.67 [2.16; 14.85] 5.67[2.16; 14.85]CheckMate 238, 2017 (REV)10%905NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-06-20 05:07 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 2,283,284,70,235,285,68,127,128,286,69,129 - treatments: 558

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons